Sugi Predict

Sugi Predict / Compounds / SCHEMBL3511512

SCHEMBL3511512

SCHEMBL3511512

Cc1noc(C)c1S(=O)(=O)Cc1csc(NC(=O)NCc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX7 Q99572 2/20 0.48
▸ ROCK1 Q13464 9/20 0.41
▸ ROCK2 O75116 8/20 0.41
▸ NAMPT P43490 1/20 0.40
▸ TRPV1 Q8NER1 3/20 0.39
▸ AKT1 P31749 2/20 0.39
▸ GSK3B P49841 2/20 0.39
▸ LIMK1 P53667 2/20 0.39
▸ CDC42BPA Q5VT25 2/20 0.39
▸ SGK1 O00141 1/20 0.39
▸ TNK2 Q07912 1/20 0.39
▸ DMPK Q09013 1/20 0.39
▸ MYLK Q15746 1/20 0.39
▸ AURKA O14965 1/20 0.38
▸ DYRK3 O43781 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ PRKCG P05129 1/20 0.38
▸ PRKACA P17612 1/20 0.38
▸ RPS6KB1 P23443 1/20 0.38
▸ MARK3 P27448 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL352910 0.87 P2RX7 (0.45) P2RX7ROCK1ROCK2NAMPTMAPK1
SCHEMBL3511222 0.86 ROCK1 (0.45) ROCK1ROCK2TRPV1AKT1GSK3B
SCHEMBL3511888 0.85 ROCK2 (0.52) ROCK1ROCK2NAMPTAKT1GSK3B
SCHEMBL3511157 0.83 ROCK1 (0.48) ROCK1ROCK2NAMPTTRPV1AKT1
SCHEMBL3512328 0.81 ROCK1 (0.41) ROCK1ROCK2NAMPTTRPV1AKT1
SCHEMBL3511581 0.81 ROCK1 (0.50) ROCK1ROCK2NAMPTTRPV1AKT1
SCHEMBL3513516 0.81 ROCK2 (0.50) ROCK1ROCK2NAMPTTRPV1AKT1
SCHEMBL4780492 0.80 P2RX7 (0.54) P2RX7ROCK1ROCK2TRPV1AKT1
SCHEMBL4780493 0.80 P2RX7 (0.54) P2RX7ROCK1ROCK2TRPV1AKT1
SCHEMBL3513135 0.80 ROCK1 (0.49) ROCK1ROCK2TRPV1AKT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293919-B2 Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-10-23 — — US claimed
US-20100286169-A1 Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2010-11-11 — — US claimed
WO-2009015193-A1 ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO claimed
US-8293919-B2 Antibacterial sulfone and sulfoxide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-10-23 — — US disclosed
US-20100286169-A1 Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2010-11-11 — — US disclosed
WO-2009015193-A1 ANTIBACTERIAL SULFONE AND SULFOXIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286169-A1 Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds TST, UMPS, UROD P2RX7 3082/4885ROCK1 4658/4885ROCK2 4700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.